Page 14 - IPO Analysis - Private Equity Exits 2017_Final

Private equity exits via IPO in

2017

Private Equity
IPO Sell Down as a Price Aggregate Total Estimated Sponsor lock-up
Private Equity Market Cap Size proportion of Change Sponsor Expenses (incl. Private Equity Sponsor + Orderly
Date Company Sector Banks Underwritten Commission / Fee Structure Relationship Agreement
Sponsor(s) at IPO (£m) (£M) IPO (%) Since IPO Retained Stake Commissions) (Key Terms) Market Periods
(%) at IPO (%) (£m) (Months from
IPO)
Destiny Pharmaceuticals, Rosetta Capital V GP 64.5 14.0 No sell down -6.3 7.62 Cantor No Placing commissions and fees not 1.3 N/A 12+12
04.09.17
Pharma plc biotechnology and Limited Fitzgerald disclosed
healthcare Europe
appScatter Computer and Perpetuity Startups 41.1 7.8 No sell down -26.15 2.61 Smith & No Smith & Williamson will be paid: 1.2 N/A 12+0
05.09.17
Group plc electronic equipment LLC Williamson, - Corporate finance fee of £205,000
Stifel
- Commission of 4% in respect of new
placees procured by them
- Commission of 1% in respect of
existing placees procured by them
- Commission of 0.65% on aggregate
of all placing shares
- Nomad and broker fee of £40,000
per annum
Stifel will be paid:
- Corporate finance fee of £100,000
- Commission of 4% in respect of
placees procured by them
- Discretionary commission of 0.5% on
aggregate of all placing shares

Private & Confidential. Not for distribution.
© DWF LLP 2018 14